MetrioPharm AG is a pharmaceutical development company focusing on therapies for chronic inflammatory diseases. We are developing a new class of self-regulating drugs against cellular oxidative stress.
Oxidative stress is one of the central causes of chronic inflammation, triggering a variety of diseases such as arthritis, dementia, cardiovascular disease and other degenerative age-related indications. MetrioPharm AGs develop...
MetrioPharm AG is a pharmaceutical development company focusing on therapies for chronic inflammatory diseases. We are developing a new class of self-regulating drugs against cellular oxidative stress.
Oxidative stress is one of the central causes of chronic inflammation, triggering a variety of diseases such as arthritis, dementia, cardiovascular disease and other degenerative age-related indications. MetrioPharm AGs development strategy is aimed specifically at these age-related inflammatory conditions.
Our lead compound MP1032 is in Phase II clinical development and has demonstrated therapeutic efficacy and an exceptional.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.